We could not find any results for:
Make sure your spelling is correct or try broadening your search.
By Jonathan D. Rockoff The maker of an EpiPen rival said its emergency allergy treatment would return to the market on Feb. 14, adding more competition to the market for the costly products...
By Jonathan D. Rockoff The maker of an EpiPen rival said its emergency allergy treatment would return to the market on Feb. 14, adding more competition to the market for the costly products...
By Anne Steele and Joseph Walker A top U.S. health insurer has dropped its coverage of Mylan NV's brand-name EpiPen and switched to the half-priced version Mylan launched in response to...
A Justice Department probe of possible price collusion by generic drug companies could lead to criminal charges by the end of the year, Bloomberg News reported Thursday. The investigation spans...
Teva Pharmaceutical Industries Ltd. is based in Israel. "Teva, Allergan Get FTC Approval for Generics Purchase," at 3:21 p.m. ET as well as subsequent updates, misspelled the...
Teva Pharmaceutical Industries Ltd. on Wednesday won regulatory approval from the Federal Trade Commission for its acquisition of Allergan PLC's generics business, conditioned upon...
By Lisa Beilfuss Teva Pharmaceutical Industries Ltd. on Wednesday won regulatory approval from the Federal Trade Commission for its acquisition of Allergan PLC's generics business...
Teva Pharmaceutical Industries Ltd., which is working toward a $40.5 billion acquisition of Allergan PLC's generics unit, increased its second-quarter earnings and revenue guidance on...
Canadian Pacific Railway Railroad Warns On Weaker Results Canadian Pacific Railway Ltd. warned on Tuesday its second-quarter results would take a hit from declining shipping volumes amid a...
Impax Laboratories Inc. said Tuesday that it would buy a portfolio of generic drugs from Israel's Teva Pharmaceutical Industries Ltd. and Allergan PLC for $586 million as Teva works to...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions